Campylobacter species are the most common bacterial cause of foodborne disease in Australia and other industrialized countries [1] [2] [3] and constitute a substantial health burden. The incidence of reported cases in Australia was 116.5 cases per 100,000 persons in 2003 [1] , and ∼277,000 cases of Campylobacter infection are estimated to occur annually [4] .
In Europe and the United States, increasing proportions of patients are infected with strains of Campylobacter species exhibiting antimicrobial resistance, particularly resistance to fluoroquinolones [2, 5] . Antimicrobial resistance may add to the burden of disease; fluoroquinolone-resistant organisms have been reported to be associated with more-severe disease [6] , including diarrhea of a longer duration [7] and an increased likelihood of invasive disease and death [8] . The rising incidence of fluoroquinolone resistance has been attributed to the use of fluoroquinolones in foodproducing animals [5] and has been reflected in the high prevalence of ciprofloxacin-resistant animal Campylobacter isolates in animals in those countries [9] .
Surveillance of antimicrobial resistance is important for monitoring trends. Data regarding antimicrobial resistance among Campylobacter isolates in Australia are limited, and studies have been confined to specific geographic regions [10] [11] [12] . Resistant isolates are not common, and fluoroquinolone resistance has not been detected previously among locally acquired isolates [12] .
The aim of this study was to estimate the prevalence of antimicrobial resistance among Australian isolates of Campylobacter jejuni. Australia is in an almost unique position in that it is has prohibited fluoroquinolones from being used in food-producing animals, although it has animal production and food production systems comparable to those of other developed nations. By measuring the prevalence of fluoroquinolone resistance among C. jejuni isolates obtained from Australian patients, some insight might be gained into the benefit of stricter control over the use of medically important antimicrobials in food animals. Prevalence of resistance was examined for Campylobacter isolates obtained from patients from 5 jurisdictions, representing ∼60% of the Australian population, over a 1-year period and was compared by travel status and jurisdiction.
METHODS

Study population.
Campylobacter isolates were collected from case-patients enrolled in a multicenter, prospective, case-control study of sporadic infection (to be reported separately Patients were excluded if they could not be contacted, their parents were not English speakers, they could not answer questions (e.g., because of dementia or because they were deceased), they could not recall the date of onset of their diarrhea, onset was у10 days before the specimen was collected, they could not be interviewed within 30 days after onset, another member of the household had had diarrhea or had been diagnosed with Campylobacter infection in the previous 4 weeks, they had a mixed infection (i.e., an additional diarrheal pathogen was simultaneously detected), they were part of an outbreak, or they refused consent. A telephone-administered questionnaire was used to document exposures for the 7 days before onset of illness. Questions included details of overseas travel (country visited and travel dates), demographic characteristics (age and sex), severity of illness (duration of diarrhea, bloody stools, fever, and vomiting), care management (hospital admission and duration of hospitalization), consumption of antimicrobial agents in the 4 weeks before onset, and underlying diseases.
Laboratory methods. The Campylobacter isolates were transported from the clinical laboratory to the state public health laboratory for storage and additional testing. C. jejuni isolates were distinguished from non-jejuni species at each public health laboratory using PCR that targeted the HipO gene [13] , and only C. jejuni isolates (subspecies jejuni or doylei) were included in the study.
Susceptibility testing was performed at each public health laboratory by the agar dilution method using Mueller-Hinton agar with 5% lysed sheep blood, in accordance with National Committee for Clinical Laboratory Standards (now called Clinical and Laboratory Standards Institute [CLSI]), as described elsewhere [14] . MICs were defined as the lowest concentration giving complete inhibition of visible growth. Antimicrobial agents tested and breakpoints denoting resistance were as follows: nalidixic acid, у32 mg/L; ciprofloxacin, у4 mg/L; tetracycline, у16 mg/L; ampicillin, у32 mg/L; erythromycin, у8 mg/L; roxithromycin, у8 mg/L; gentamicin, у8 mg/L; kanamycin, у32 mg/L; chloramphenicol, у32 mg/L; and sulfisoxazole, у 350 mg/L. Because there are no recommended breakpoints specifically for Campylobacter species, the CLSI breakpoints for Enterobacteriaceae were used, except for erythromycin, for which the breakpoint for Staphylococcus was used [14] .
Before the study began, a set of 8 isolates that had been previously tested for susceptibility to 7 of the 10 agents used in the study [10] were tested by each laboratory to ensure reproducibility of results. During the testing of study isolates, C. jejuni NCTC 11351 (same isolate as the CLSI-recommended ATCC 33560 [15] ) was included as the control in each test batch.
Statistical analyses. We compared the following: (1) patients infected with ciprofloxacin-resistant isolates and patients infected with susceptible isolates; (2) the prevalence of resistance among locally acquired isolates and the prevalence among isolates acquired overseas; and (3) the severity of disease among patients infected with ciprofloxacin-susceptible Campylobacter and the severity of disease among patients infected with ciprofloxacin-resistant Campylobacter. The following severity indicators were examined: duration of diarrhea, presence of blood in the stool, fever and vomiting, hospitalization, and length of hospital stay. The 95% CIs for prevalence and ORs were based on standard large sample methods for estimates of proportions. Exact methods were used when counts were small. In particular, Fisher's exact test was used to the compare prevalence of antimicrobial resistance in locally acquired isolates with the prevalence of resistance in travel-acquired isolates. Prevalences of resistance among isolates from locally acquired infections were compared across jurisdictions and by antimicrobial exposure status using likelihood ratio tests based on logistic regression, with potential confounders included in the analyses.
Logistic regression was also used to compare dichotomous measures of severity of illness, such as hospitalization and blood in stool, whereas standard linear regression was used to compare continuous measures, such as duration of illness and length of hospital stay. Statistical analyses were performed using STATA, version 9.1 (Stata).
RESULTS
The characteristics of the study population, including the number of cases of Campylobacter infection reported during the study period, the number of case-patients recruited, and the proportion of isolates tested, are summarized by state in table 1 . Of the 585 isolates tested, 279 (48%) were from female patients, and the median age was 32 years (range, 0-93 years).
The proportion of Campylobacter isolates tested for antimicrobial susceptibility from reported case-patients from each state ranged from 3% in Victoria to 14% in South Australia. The population under surveillance in the 5 participating states comprised ∼64% of the Australian population in 2001.
Prevalences of resistance to the 10 antimicrobial agents among locally acquired isolates is shown in table 2. Sulfisoxazole resistance was the most common (55% of isolates), and only 2% of isolates were resistant to ciprofloxacin.
Ciprofloxacin resistance was found among locally acquired isolates from all states except Tasmania (table 2). All 14 locally acquired isolates were also resistant to nalidixic acid, and 10 (71%) were resistant to 11 class of antimicrobial agent (table  3) . Temporal clusters of infection were detected in Victoria (November-December 2001 and January-February 2002) and in South Australia (May 2002), but a variety of resistance phenotypes were detected in these clusters, indicating that the isolates were unlikely to be related (table 3) . The prevalence of ciprofloxacin resistance in Victoria was higher than in all other states combined (9% vs. 2%; OR, 6.2; 95% CI, 2.1-18.5), but this significant difference should be interpreted with care, because it is a post hoc comparison. When controlling for jurisdiction, patients infected with ciprofloxacin-resistant isolates were more likely to have an underlying disease than those infected with ciprofloxacin-susceptible isolates (OR 5.1; 95% CI, 1.5-17.3).
People who acquired Campylobacter infections overseas were more likely to be infected with resistant strains; 9 (82%) of 11 overseas-acquired isolates were resistant to 11 class of antimicrobial agent, compared with 291 (51%) of 574 locally acquired isolates (OR, 4.4; 95% CI, 0.9-41.9). Resistances to ciprofloxacin and tetracycline were significantly more prevalent among overseas-acquired isolates than they were among locally acquired isolates: ciprofloxacin, 64% vs. 2% (OR, 67.5; 95% CI, 15.2-351.6); and tetracyline, 55% vs. 7% (OR, 16.7; 95% CI, 4.0-72.6). Nine of 11 patients had travelled to Asia (Indonesia, Malaysia, Singapore, Thailand, and Vietnam) during the week before onset of illness; the remaining 2 patients had travelled to Africa and North and South America (data not shown).
Patients infected with locally acquired ciprofloxacin-resistant strains were no more likely to have taken an antimicrobial agent in the 4 weeks before onset, compared with patients infected with ciprofloxacin-susceptible isolates (6% vs. 7%; OR, 1.3; 95% CI, 0.2-10.2). No patient infected with a ciprofloxacinresistant isolate had taken a fluoroquinolone in the 4 weeks before onset of illness. Nine (64%) of 14 patients with ciprofloxacin-resistant isolates were given antibiotic therapy for their Campylobacter infection, compared with 222 (40%) of 549 patients with ciprofloxacin-susceptible isolates; however, this difference did not reach statistical significance (OR, 2.5; 95% CI, 0.9-7.1).
Infection with a ciprofloxacin-resistant strain of C. jejuni did not result in a more-severe illness, but the number of patients that were infected with a ciprofloxacin-resistant strain of C. jejuni was small. There were no significant differences in the distribution of symptoms; compared with patients infected ciprofloxacin-susceptible strains, patients infected with ciprofloxacin-resistant strains were no more likely to have fever (68% vs. 74%; OR, 1.6; 95% CI, 0.4-5.9), or vomiting (38% vs. 35%; OR, 1.6; 95% CI, 0.6-4.5), or bloody stools (15% vs. 42%; OR, 0.4; 95% CI, 0.1-5.4). Duration of diarrhea was similar for patients infected with ciprofloxacinresistant strains and patients infected with ciprofloxacin-sensitive strains (median duration for both groups, 7 days; ), as were the percentage of patients requiring hos-P p .63 pitalization (14% vs. 13%; OR, 0.8; 95% CI, 0.2-3.6) and the length of hospital stay (median duration for both groups, 0 days; ) in multivariate models controlling for age and P p .13 underlying disease, regardless of travel status.
DISCUSSION
This is the first Australian study to report locally acquired Campylobacter isolates resistant to fluoroquinolones. However, the prevalence of ciprofloxacin resistance among locally acquired isolates in Australia was low at 2% and ranged from 0% to 8% across 5 states. The absence of ciprofloxacin-resistant isolates in locally acquired infections in Australia has been attributed previously to restricting the use of fluoroquinolones in food-producing animals. Data regarding antimicrobial susceptibility among Campylobacter isolates infecting Australian food-producing animals is limited; however, Campylobacter isolates (all species) from pigs have been shown to be uniformly susceptible to ciprofloxacin [17] , likely reflecting the low prevalence of resistance in isolates obtained from Australian animals. The prevalence is similar to that described for humans from Sweden (between 0% and 9%), where the use of antibiotics as growth promoters was banned in 1986 [18] . A low prevalence of ciprofloxacin resistance was also found among isolates obtained from Swedish animals [9] . Among studies that have separated locally acquired from travel-acquired isolates, in countries that have allowed the use of fluoroquinolones for animals, the prevalence of locally acquired ciprofloxacin resistance ranges from 7% to 29% [3, 19] . The overall prevalence of ciprofloxacin resistance is much higher in some countries, probably reflecting widespread use of ciprofloxacin in humans in those regions. These regions include countries in which Australian travellers are likely to acquire infection; for example, 180% of clinical isolates in Thailand have been reported to be ciprofloxacin resistant [5] , and 35% of clinical isolates in Indonesia were ciprofloxacin resistant [20] . The source of resistant isolates from locally acquired infections is unclear. It is possible that the case-patient had been overseas 17 days before the onset of illness or had direct contact with a recently returned traveller; however, person-to-person transmission is uncommon [21] . Other possible sources include consumption of contaminated, imported food or acquisition of resistance during a hospital stay. However, only 2 of the 14 patients infected with ciprofloxacin-resistant isolates had been admitted to a hospital for treatment. Furthermore, only cooked chicken is permitted for importation into Australia [12] , and viable Campylobacter organisms are unlikely to be present.
Previous studies have shown that treatment of patients with quinolones after onset of illness but before collection of the stool specimen is associated with detection of quinolone-resistant isolates [22] . We did not collect information on the timing of antimicrobial treatment or the agent used. However, patients with ciprofloxacin-resistant isolates were significantly more likely to have been given antibiotic therapy for their infection than were patients infected with susceptible isolates, and ciprofloxacin is commonly used in Australia for the treatment of enteric infections. Therefore, this explanation is plausible.
Three previous Australian studies that reported travel histories of patients examined 153, 140, and 50 isolates, respectively [12] ; the sample sizes in these studies may have been insufficient to detect a low prevalence of resistant isolates. The reasons for variation in the apparent prevalence of locally acquired ciprofloxacin-resistant isolates by state of residence are unclear and require further study.
Resistance to sulfisoxazole, ampicillin, and roxithromycin was detected commonly among isolates obtained from patients that acquired their infections locally. The prevalence of ampicillin resistance in this study (46%) was similar to that reported in previous Australian studies [10, 11] and studies from the United Kingdom [23] . Low levels of resistance were detected for erythromycin, chloramphenicol, gentamicin, and kanamycin, as reported in Australia [10, 24] and elsewhere [18, 19, 23, 25] . Tetracycline resistance was low, which contrasts with findings from the United States [25] but is similar to findings from Europe [18, 19, 26] . Isolates from travel-associated cases were more commonly resistant to nalidixic acid, ciprofloxacin, and tetracycline than were isolates from locally acquired cases, as found previously in Australia [10] and Denmark [19] . Isolates resistant to nalidixic acid and susceptible to ciprofloxacin were found among travel-acquired and locally acquired isolates, as found in other studies [10, 23] . Six percent of case-patients had taken an antimicrobial agent in the 4 weeks before onset of illness, but there was no association between this and ciprofloxacin resistance.
In our study, infection with a ciprofloxacin-resistant isolate was not associated with increased severity of illness; this contrasts with a study from the United States, in which a similar number of patients infected with ciprofloxacin-resistant organisms was more likely to be hospitalized and have bloody diarrhea [25] than were patients infected with susceptible isolates. A study [7] that described patients infected with ciprofloxacinresistant isolates who had prolonged diarrhea included 63 patients; it is possible that the larger sample size raised the statistical power of the study to detect a difference.
There are some limitations in generalizing the results of this study to the Australian population. First, patients included in this study were identified through notifications and were, therefore, more likely to have had relatively severe infections, leading to presentation and a stool test. Second, we relied on self-reported information regarding overseas travel, antimicrobial therapy, and clinical symptoms, and this information was not validated. However, the potential measurement bias resulting from this method was likely to be nondifferential (i.e., occurring equally among patients infected with resistant and susceptible strains).
In summary, antimicrobial resistance among Australian strains of C. jejuni is uncommon, excepting resistance to ampicillin, roxithromycin, and sulfisoxazole. Of particular importance is that resistance to fluoroquinolone is very low and probably reflects Australia's policy of prohibiting fluoroquinolones for animal use. Sensible use of fluoroquinolones in clinical treatment remains a high priority if a low prevalence of resistance in C. jejuni and other organisms is to be maintained. The United States withdrew approval for the use of fluoroquinolones in animals following reports between 1994 and 1996 of the increasing levels of fluoroquinolone resistance. Such a policy should be considered for wider adoption. The detection of ciprofloxacin resistance among locally acquired infections warrants additional investigations and ongoing surveillance. 
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